Switzerland has cut the price of 257 original medicines by an average of 16.3%, generating savings of 100 million francs

Every three years the Federal Office of Public Health (FOPH) reviews the reimbursement conditions and, more specifically, the prices of the medicines in the list of specialities covered by the compulsory health insurance (OKP). The medicines are split into three equal groups, containing distinct therapeutic groups and comprised of approximately 1000 medicines in each.

The medicines most recently reviewed are from the therapeutic groups of heart and circulation, infectiology and ophthalmology. Over half (54%) of the medicines reviewed were subjected to a price cut, with the remaining medicines still considered as economical compared to the reference countries and other medicines. The price cuts are estimated to make savings of 100 million francs in 2019.

Next year, the triennial review begins again and will start with reviewing medicines from therapeutic groups of gastroenterology and oncology, among others.

By Tom Brockbank – Consultant, P&MA

Link to FOPH media release: https://www.admin.ch/gov/de/start/dokumentation/medienmitteilungen.msg-id-76806.html